VILLA GUARDIA, Italy, Nov. 10, 2010 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that three abstracts on Defibrotide will be presented at the 52 nd Annual Meeting and Exposition of the American Society of Hematology to be held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

Poster session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Poster II, Hall A3/A4, Monday, December 6, 2010, 6:00 PM - 8:00 PM

"Meta-analysis of Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with comparison to a Historical Control (HC)" (Poster Board III-260). P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

"Safety of Defibrotide (DF) in Stem Cell Transplant (SCT) patients (Pts)" (Poster Board III-261). S. Corbacioglu et al., University of Regensburg, Regensburg, Germany.

Oral session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Transplant Related Toxicities, Room 110A, Tuesday, December 7, 2010, 8:45 AM

"Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): results of a treatment IND expanded access protocol" (Abstract #906), P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

For more details on the congress, please visit the official congress web site:

http://www.hematology.org/Meetings/Annual-Meeting/

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.